Literature DB >> 32062666

An Integrated View on Vascular Dysfunction in Alzheimer's Disease.

Jan Klohs1,2.   

Abstract

BACKGROUND: Cerebrovascular disease is a common comorbidity in patients with Alzheimer's disease (AD). It is believed to contribute additively to the cognitive impairment and to lower the threshold for the development of dementia. However, accumulating evidence suggests that dysfunction of the cerebral vasculature and AD neuropathology interact in multiple ways. Vascular processes even proceed AD neuropathology, implicating a causal role in the etiology of AD. Thus, the review aims to provide an integrated view on vascular dysfunction in AD.
SUMMARY: In AD, the cerebral vasculature undergoes pronounced cellular, morphological and structural changes, which alters regulation of blood flow, vascular fluid dynamics and vessel integrity. Stiffening of central blood vessels lead to transmission of excessive pulsatile energy to the brain microvasculature, causing end-organ damage. Moreover, a dysregulated hemostasis and chronic vascular inflammation further impede vascular function, where its mediators interact synergistically. Changes of the cerebral vasculature are triggered and driven by systemic vascular abnormalities that are part of aging, and which can be accelerated and aggravated by cardiovascular diseases. Key Messages: In AD, the cerebral vasculature is the locus where multiple pathogenic processes converge and contribute to cognitive impairment. Understanding the molecular mechanism and pathophysiology of vascular dysfunction in AD and use of vascular blood-based and imaging biomarker in clinical studies may hold promise for future prevention and therapy of the disease.
© 2020 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Alzheimer’s disease; Blood-brain barrier; Coagulation; Inflammation; Vasculature

Year:  2020        PMID: 32062666     DOI: 10.1159/000505625

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  16 in total

1.  Amyloid [Formula: see text] (1-42) peptide impairs mitochondrial respiration in primary human brain microvascular endothelial cells: impact of dysglycemia and pre-senescence.

Authors:  Siva S V P Sakamuri; Venkata N Sure; Xiaoying Wang; Gregory Bix; Vivian A Fonseca; Ricardo Mostany; Prasad V G Katakam
Journal:  Geroscience       Date:  2022-08-17       Impact factor: 7.581

2.  Altered Blood and Brain Expression of Inflammation and Redox Genes in Alzheimer's Disease, Common to APPV717I × TAUP301L Mice and Patients.

Authors:  Catalina Anca Cucos; Elena Milanesi; Maria Dobre; Ioana Andreea Musat; Gina Manda; Antonio Cuadrado
Journal:  Int J Mol Sci       Date:  2022-05-21       Impact factor: 6.208

Review 3.  Causes and consequences of baseline cerebral blood flow reductions in Alzheimer's disease.

Authors:  Oliver Bracko; Jean C Cruz Hernández; Laibaik Park; Nozomi Nishimura; Chris B Schaffer
Journal:  J Cereb Blood Flow Metab       Date:  2021-01-14       Impact factor: 6.200

4.  Optical coherence tomography angiography in Alzheimer's disease: a systematic review and meta-analysis.

Authors:  Andreas Katsimpris; Aristotelis Karamaounas; Anna Maria Sideri; John Katsimpris; Ilias Georgalas; Petros Petrou
Journal:  Eye (Lond)       Date:  2021-06-30       Impact factor: 4.456

Review 5.  The biological pathways of Alzheimer disease: a review.

Authors:  Marco Calabrò; Carmela Rinaldi; Giuseppe Santoro; Concetta Crisafulli
Journal:  AIMS Neurosci       Date:  2020-12-16

Review 6.  Research Progress on Mechanism of Neuroprotective Roles of Apelin-13 in Prevention and Treatment of Alzheimer's Disease.

Authors:  Teng Wan; Mingyuan Fu; Yan Jiang; Weiwei Jiang; Peiling Li; Shouhong Zhou
Journal:  Neurochem Res       Date:  2021-09-13       Impact factor: 3.996

7.  Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting.

Authors:  Michelle Kokkinou; Lucy C Beishon; Nadja Smailagic; Anna H Noel-Storr; Chris Hyde; Obioha Ukoumunne; Rosemary E Worrall; Anja Hayen; Meera Desai; Abhishekh Hulegar Ashok; Eleanor J Paul; Aikaterini Georgopoulou; Tiziana Casoli; Terry J Quinn; Craig W Ritchie
Journal:  Cochrane Database Syst Rev       Date:  2021-02-10

8.  X-ray Phase Contrast Tomography Serves Preclinical Investigation of Neurodegenerative Diseases.

Authors:  Francesca Palermo; Nicola Pieroni; Laura Maugeri; Ginevra Begani Provinciali; Alessia Sanna; Lorenzo Massimi; Maura Catalano; Margie P Olbinado; Inna Bukreeva; Michela Fratini; Antonio Uccelli; Giuseppe Gigli; Nicole Kerlero de Rosbo; Claudia Balducci; Alessia Cedola
Journal:  Front Neurosci       Date:  2020-11-09       Impact factor: 4.677

Review 9.  GABAergic dysfunction, neural network hyperactivity and memory impairments in human aging and Alzheimer's disease.

Authors:  Joan Jiménez-Balado; Teal S Eich
Journal:  Semin Cell Dev Biol       Date:  2021-02-09       Impact factor: 7.727

10.  The Cause of Alzheimer's Disease: The Theory of Multipathology Convergence to Chronic Neuronal Stress.

Authors:  Boris Decourt; Gary X D'Souza; Jiong Shi; Aaron Ritter; Jasmin Suazo; Marwan N Sabbagh
Journal:  Aging Dis       Date:  2022-02-01       Impact factor: 9.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.